Yahoo
BSE - Delayed Quote INR

Mankind Pharma Limited (MANKIND.BO)

2,488.75 +27.55 (+1.12%)
At close: October 30 at 3:28:50 PM GMT+5:30
Chart Range Bar
Loading chart for MANKIND.BO
  • Previous Close 2,461.20
  • Open 2,482.95
  • Bid 2,479.85 x --
  • Ask 2,500.00 x --
  • Day's Range 2,472.55 - 2,527.80
  • 52 Week Range 1,909.90 - 2,640.30
  • Volume 15,799
  • Avg. Volume 50,705
  • Market Cap (intraday) 1.028T
  • Beta (5Y Monthly) 0.44
  • PE Ratio (TTM) 45.88
  • EPS (TTM) 54.24
  • Earnings Date (est.) Jan 26, 2027
  • Forward Dividend & Yield 2.00 (0.00%)
  • Ex-Dividend Date Aug 8, 2025
  • 1y Target Est 2,703.26

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

www.mankindpharma.com

20,451

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

MANKIND.BO
13.31%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

MANKIND.BO
1.76%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

MANKIND.BO
42.00%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

MANKIND.BO
91.44%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY27
Revenue 43.38B
Earnings 7.11B
Profit Margin 16.40%

Q3

FY26

Q4

FY26

Q1

FY27

Q2

FY27

0
10B
20B
30B
40B
12.0%
13.0%
14.0%
15.0%
16.0%

Analyst Insights

View More

Analyst Price Targets

2,057.00 Low
2,703.26 Average
2,488.75 Current
3,280.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.58%

  • Return on Assets (ttm)

    7.05%

  • Return on Equity (ttm)

    13.56%

  • Revenue (ttm)

    153.79B

  • Net Income Avi to Common (ttm)

    22.43B

  • Diluted EPS (ttm)

    54.24

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    26.6B

  • Total Debt/Equity (mrq)

    30.36%

  • Levered Free Cash Flow (ttm)

    17.29B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: